DBS of Thalamic Centromedian Nucleus for Lennox–Gastaut Syndrome (ESTEL Trial)

Objective Prior uncontrolled studies have reported seizure reductions following deep brain stimulation (DBS) in patients with Lennox–Gastaut syndrome (LGS), but evidence from randomized controlled studies is lacking. We aimed to formally assess the efficacy and safety of DBS to the centromedian thalamic nucleus (CM) for the treatment of LGS. Methods We conducted a prospective, double‐blind, randomized study of continuous, cycling stimulation of CM‐DBS, in patients with LGS. Following pre‐ and post‐implantation periods, half received 3 months of stimulation (blinded phase), then all received 3 months of stimulation (unblinded phase). The primary outcome was the proportion of participants with ≥50% reduction in diary‐recorded seizures in stimulated versus control participants, measured at the end of the blinded phase. A secondary outcome was the proportion of participants with a ≥50% reduction in electrographic seizures on 24‐hour ambulatory electroencephalography (EEG) at the end of the blinded phase. Results Between November 2017 and December 2019, 20 young adults with LGS (17–37 years;13 women) underwent bilateral CM‐DBS at a single center in Australia, with 19 randomized (treatment, n = 10 and control, n = 9). Fifty percent of the stimulation group achieved ≥50% seizure reduction, compared with 22% of controls (odds ratio [OR] = 3.1, 95% confidence interval [CI] = 0.44–21.45, p = 0.25). For electrographic seizures, 59% of the stimulation group had ≥50% reduction at the end of the blinded phase, compared with none of the controls (OR= 23.25, 95% CI = 1.0–538.4, p = 0.05). Across all patients, median seizure reduction (baseline vs study exit) was 46.7% (interquartile range [IQR] = 28–67%) for diary‐recorded seizures and 53.8% (IQR = 27–73%) for electrographic seizures. Interpretation CM‐DBS in patients with LGS reduced electrographic rather than diary‐recorded seizures, after 3 months of stimulation. Fifty percent of all participants had diary‐recorded seizures reduced by half at the study exit, providing supporting evidence of the treatment effect. ANN NEUROL 2022;91:253–267